Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Continuous access to radiation treatment is vital for patients with aggressive cancers, such as those with locally advanced non-small cell lung cancer (NSCLC), who require daily treatments to ...

Each year, 50,000 new lung cancer cases are diagnosed in France, with non–small cell lung cancer (NSCLC ... Among the major advances presented at the congress were the findings from the ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC ... But, is it possible to know if the treatment will be effective in all those affected?

Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC ... But, is it possible to know if the treatment will be effective in all those affected?